Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA May Allow Furberg To Participate In COX-2 Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

No final decision has been made on the drug safety committee member's eligibility for the early 2005 meeting, FDA maintains. Acting Commissioner Crawford backs away from early statements that Furberg would not participate.

You may also be interested in...



FDA COX-2 Review Will Include Input From Furberg, Full Rx Safety Advisory Cmte.

After initially being asked not to appear at the meeting, Wake Forest's Furberg is formally re-invited to participate at the Feb 16-18 advisory committee meeting. FDA first invited only two members of the drug safety committee but has expanded its invitation to the full committee.

FDA COX-2 Review Will Include Input From Furberg, Full Rx Safety Advisory Cmte.

After initially being asked not to appear at the meeting, Wake Forest's Furberg is formally re-invited to participate at the Feb 16-18 advisory committee meeting. FDA first invited only two members of the drug safety committee but has expanded its invitation to the full committee.

Bextra Meta-Analyses Could Be Taken Up At February COX-2 Advisory Cmte.

Drug safety committee member Curt Furberg's meta-analysis suggests increased risk of cardiovascular events for patients with osteoarthritis and rheumatoid arthritis taking Bextra versus placebo while Pfizer points to a meta-analysis of 8,000 patients that did not show an effect. Furberg disinvited by FDA to participate in committee meeting following public comments.

Topics

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel